TOKYO - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter 'ASKA') is pleased to announce that it has completed the acquisition 24.9% shares of the Vietnamese pharmaceutical company, Ha Tay Pharmaceutical Joint Stock Company, and Hataphar became an affiliate company of ASKA under accounting rules for the equity method.
Overview of Share Acquisition
Number of Shares 6,575,421 (24.9%)
Acquisition Cost Not disclosed, based on confidentiality obligations in the share transfer agreement.
Overview of Hataphar
Company Name Ha Tay Pharmaceutical Joint Stock Company
Businesses Manufacturing, sales and importation of pharmaceuticals, nonprescription and nutraceutical products
Capital 211,274 million VND (1.01billion yen
Establishment 1965
Headquarters Hanoi, Vietnam
Net Sales (FY2019) 2,042,749,649,511 VND (9.80 billion yen)
Net Income (FY2019) 90,022,812,337 VND (0.43 billion yen)
Equity (FY2019) 312,146,627,850 VND (1.50 billion yen)
Total Assets (FY2019) 738,220,433,620 VND (3.54 billion yen)
Schedule
Share Acquisition Date January 15th, 2021
Future Financial Outlook
The impact of this Share Acquisition on the consolidated results of ASKA for FY2020 will be minor.
Contact:
Tel: +81 466-77-8336
Fax: +81 466-26-5879
(C) 2021 Electronic News Publishing, source ENP Newswire